Bexorg Wins Up to $28.3M ARPA-H Grant for Brain Drug Research
Bexorg receives a federal award to extend human brain tissue preservation technology, potentially reshaping how CNS drugs are developed and tested.
Bexorg has been awarded up to $28.3 million from the Advanced Research Projects Agency for Health (ARPA-H) to advance human brain translational pharmacology, the company announced. The funding is structured as a three-phase, 36-month contract aimed at accelerating the development of central nervous system therapeutics.
At the core of the project is Bexorg's BrainEx perfusion technology, which currently keeps human brain tissue viable for up to 24 hours outside the body. The ARPA-H award is designed to push that preservation window dramatically further — to as long as two weeks — a leap that researchers say could fundamentally change how brain biology is studied and how candidate drugs are evaluated before clinical trials.
Read more Foundation Group Merges Two Units Into Nonprofit Accounting Division →
Extending the viability window to 14 days would enable longitudinal studies on living human brain tissue, allowing scientists to observe how the brain responds to experimental therapies over time rather than in a single, brief snapshot. That capability addresses a long-standing bottleneck in CNS drug development, where the gap between animal models and human biology has contributed to high failure rates in clinical trials.
The ARPA-H investment signals growing federal interest in bridging translational gaps in neuroscience research. CNS disorders — including Alzheimer's disease, Parkinson's disease, and treatment-resistant depression — represent some of the most commercially and scientifically challenging areas in medicine, with decades of drug failures attributed in part to inadequate preclinical human tissue models.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
